* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
As a leading service provider in drug discovery and research, BOC Sciences is fully capable and committed to providing one-stop proteolysis targeting molecular drug discovery based on chimeric (Protac®). With a comp rehensive and advanced platform, we provides Protac® design based on bioinformatics services to customers around the world to meet new drug discovery goals.
In order to simplify and accelerate the discovery of Protac®, it is necessary to grasp the design rules of Protac®, which is helpful to establish a reliable Protac® evaluation platform. To date, most reported Protac® designs are based on target protein-binding ligands (usually inhibitors). Because the crystal complex structure of the target protein and its binding ligand and the structure-activity relationship information of the ligand have been used to guide Protac® design, such as determining the Linker binding site of the target protein binding ligand. Recent research uses bioinformatics to guide Protac® optimization. Bioinformatics methods play an irreplaceable role in the process of drug discovery, especially for the analysis of large-scale multi-group data. at present, many disease-related database resources have emerged, and a variety of bioinformatics methods have been established to discover potential drug targets based on biological network characteristics, multi-gene chip, proteome, metabolome data and so on. The target drug availability and drug side effects were predicted.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Interested in our Service & Products?
Need detailed information?